Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
Retrieved on:
Monday, November 28, 2022
American Epilepsy Society, Seizure, Brain, EEG, Oxcarbazepine, Security (finance), Government budget balance, DEE, Intellectual disability, Neuron, Patient, Pharmacokinetics, European Medicines Agency, Șaeș, Heart rate, Cyanosis, SCN8A, NAV, Caregiver, Movement, Iňa, Fed, FDA, COVID-19, Dees, Judgement, Epilepsy, Body part as an object, Ataxia, Food, Standard electrode potential, Life, Central nervous system disease, Disease, Orphan, AES, Annual general meeting, Central nervous system, CNS, Dystonia, ODD, Movement disorders, Pharmaceutical industry, Generic drug, Part, Safety, Praxis, SCN2A
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
Key Points:
- BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
- Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
- Although Praxis forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis.
- Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.